Lilly vows appeal of Alimta patent ruling in Germany
This article was originally published in Scrip
Executive Summary
Eli Lilly will try to overturn the German Court of Appeal's ruling that its vitamin regimen patent for Alimta (pemetrexed) will not be infringed when Actavis launches a dipotassium salt form of pemetrexed after the cancer drug's compound patent expires in Germany in December.
You may also be interested in...
Lilly Executes Growth Strategy As New Products Drive Sales Gains
Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.